Wren Therapeutics is a biopharmaceutical company. It is focused on drug discovery and development for protein misfolding diseases, which include Alzheimer’s and Parkinson’s diseases, type-2 diabetes, and rare forms of amyloidosis.
|Employees (est.) (May 2021)||36||(-5%)|
Wren Therapeutics total Funding
Wren Therapeutics latest funding size
Time since last funding
|2 years ago|
Wren Therapeutics investors
|LifeForce Capital, Malin Corporation plc, The Baupost Group|
|GBP||FY, 2017||FY, 2018|
When was Wren Therapeutics founded?
Wren Therapeutics was founded in 2016.
Who are Wren Therapeutics key executives?
Wren Therapeutics's key executives are G. Kelly Martin, Michele Vendruscolo and Samuel Cohen.
How many employees does Wren Therapeutics have?
Wren Therapeutics has 36 employees.
Who are Wren Therapeutics competitors?
Competitors of Wren Therapeutics include Arch Oncology, Igyxos and Imara.
Where is Wren Therapeutics headquarters?
Wren Therapeutics headquarters is located at Clarendon Rd, Cambridge.
Where are Wren Therapeutics offices?
Wren Therapeutics has offices in Cambridge and Lund.
How many offices does Wren Therapeutics have?
Wren Therapeutics has 4 offices.
Receive alerts for 300+ data fields across thousands of companies